2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
26
Gynecologic
12
Gastrointestinal
12
Tumor-Agnostic
7
Genitourinary
7
Other solid neoplasm
6
CNS
3
Breast
3
Sarcoma
2
Other hematologic neoplasm
2
Head & Neck
2
NET
1
Endocrine
1
Dermatologic
1
Conditions
Melanoma, Cutaneous Malignant
1
Interventions
pembrolizumab
339
Nivolumab
305
Ipilimumab
274
Cyclophosphamide
195
aldesleukin
148
Interleukin-2
110
fludarabine phosphate
107
trametinib
85
Temozolomide
83
fludarabine
81
Dacarbazine
81
dabrafenib
77
Radiotherapy
75
Biopsy
75
Vemurafenib
71
Imiquimod
53
Bevacizumab
51
sargramostim
50
Magnetic Resonance Spectroscopy
50
Specimen Handling
49
Radiosurgery
49
Peripheral Blood Stem Cell Transplantation
49
Paclitaxel
49
Aminolevulinic Acid
49
binimetinib
48
Carboplatin
48
Blood Specimen Collection
47
cemiplimab
46
Cisplatin
45
3-ingenyl angelate
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
nintedanib
×
Dermatologic
×
Clear all
NCT02308553
2020-10-14
NIPAWILMA
University Hospital, Essen
Phase 1/2
Completed
33 enrolled